|
1
|
Prenen H, Tejpar S and Cutsem EV: New
strategy for treatment of KRAS mutant metastatic colorectal cancer.
Clin Cancer Res. 16:2921–2926. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang HR: Trastuzumab-based neoadjuvant
therapy in patients with HER2-positive breast cancer. Cancer.
116:2856–2867. 2010. View Article : Google Scholar
|
|
3
|
Nakazato H, Koike A, Saji S, Ogawa N and
Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment
after curative resection of gastric cancer. Lancet. 343:1122–1126.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohwada S, Ikeya T, Yokomori T, Kusaba T,
Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S,
Ishikawa H, Kawate S, Nakajima T and Morishita Y: Adjuvant
immunochemotherapy with oral tegafur/uracil plus PSK in patients
with stage II or III colorectal cancer: a randomized controlled
study. Br J Cancer. 90:1003–1010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Konno K, Motomiya M, Oizumi K, Sato M,
Yamamoto F, Tamiya K, Hasuike T, Yokosawa A, Uchiyama T, Ogawa N
and Nakai Y: Effects of protein-bound polysaccharide preparation
(PSK) in small cell carcinoma of the lung. Lung Cancer. 28:19–28.
1988.
|
|
6
|
Tsukagoshi S, Hashimoto Y, Fujii G,
Kobayashi H, Nomoto K and Orita K: Krestin (PSK). Cancer Treat Rev.
11:131–155. 1984. View Article : Google Scholar
|
|
7
|
Maehara Y, Tsujitani S, Saeki H, Oki E,
Yoshinaga K, Emi Y, Morita M, Kohnoe S, Kakeji Y, Yano T and Baba
H: Biological mechanism and clinical effect of protein-bound
polysaccharide K (KRESTIN®): review of development and
future perspectives. Surg Today. 42:8–28. 2012. View Article : Google Scholar
|
|
8
|
Lu H, Yang Y, Gad E, Wenner CA, Chang A,
Larson ER, Dang Y, Martzen M, Standish LJ and Disis ML:
Polysaccharide krestin is a novel TLR2 agonist that mediates
inhibition of tumor growth via stimulation of CD8 T cells and NK
cells. Clin Cancer Res. 17:67–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okumura K, Mekata E, Shiomi H, Naitoh H,
Abe H, Endo Y, Kurumi Y and Tani T: Expression level of thymidylate
synthase mRNA reflects 5-fluorouracil sensitivity with low dose and
long duration in primary colorectal cancer. Cancer Chemother
Pharmacol. 61:587–594. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oie S, Ono M, Fukushima H, Hosoi F, Yano
H, Maruyama Y, Kojiro M, Terada T, Hirano K, Kuwano M and Yamada Y:
Alteration of dihydropyrimidine dehydrogenase expression by IFN-α
affects the antiproliferative effects of 5-fluorouracil in human
hepatocellular carcinoma cells. Mol Cancer Ther. 6:2310–2318.
2007.PubMed/NCBI
|
|
11
|
Mizutani Y, Nakanishi H, Yoshida O,
Fukushima M, Bonavida B and Miki T: Potentiation of the sensitivity
of renal cell carcinoma cells to TRAIL-mediated apoptosis by
subtoxic concentrations of 5-fluorouracil. Eur J Cancer.
38:167–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyazaki K, Shibahara T, Sato D, Uchida K,
Suzuki H, Matsui H, Yanaka A, Nakahara A and Matsuzaki Y: Influence
of chemotherapeutic agents and cytokines on the expression of
5-fluorouracil-associated enzymes in human colon cancer cell lines.
J Gastroenterol. 41:140–150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirose K, Zachariae C, Oppenheim J and
Matsusima K: Induction of gene expression and production of
immunomodulating cytokines by PSK in human peripheral blood
mononuclear cells. Lymphokine Res. 94:475–483. 1990.PubMed/NCBI
|
|
14
|
Asai H, Iijima H, Matsunaga K, Oguchi Y,
Katsuno H and Maeda K: Protein-bound polysaccharide K augments IL-2
production from murine mesenteric lymph node CD4+ T
cells by modulating T cell receptor signaling. Cancer Immunol
Immunother. 57:1647–1655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kitani H, Trsuru S, Oka M and Zinnaka Y:
Effect of immunomodulator PSK on the production of interferon in
tumor-bearing mice. J Natl Def Med Coll. 6:30–35. 1981.
|
|
16
|
Price LA, Wenner CA, Sloper DT, Slaton JW
and Novack JP: Role of toll-like receptor 4 in TNF-alpha secretion
by murine macrophages in response to polysaccharide Krestin, a
Trametes versicolor mushroom extract. Fitoterapia.
81:914–919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trinchieri G: Type I interferon: friend or
foe? J Exp Med. 207:2053–2063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lijeroos M, Vuolteenaho R, Rounioja S,
Henriques-Normark B, Hallman M and Ojaniemi M: Bacterial ligand of
TLR2 signals Stat activation via induction of IRF1/2 and
interferon-α production. Cell Signal. 20:1873–1881. 2008.PubMed/NCBI
|
|
19
|
Barbalat R, Lau L, Locksley RM and Barton
GM: Toll-like receptor 2 on inflammatory monocytes induces type I
interferon in response to viral but not bacterial ligands. Nat
Immunol. 10:1200–1207. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagano H, Sakon M, Eguchi H, Kondo M,
Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S,
Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S and Monden M:
Hepatic resection followed by IFN-α and 5-FU for advanced
hepatocellular carcinoma with tumor thrombus in the major portal
branch. Hepatogastroenterology. 54:172–179. 2007.
|
|
21
|
Kornmann M, Staib L, Wiegel T, Kreuser ED,
Kron M, Baumann W, Henne-Bruns D and Link KH: Adjuvant
chemoradiotherapy of advanced resectable rectal cancer: results of
a randomized trial comparing modulation of 5-fluorouracil with
folic acid or with interferon-α. Br J Cancer. 103:1163–1172.
2010.
|
